These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20949074)

  • 1. Transforming growth factor-β: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis.
    Carlson CM; Turpin EA; Moser LA; O'Brien KB; Cline TD; Jones JC; Tumpey TM; Katz JM; Kelley LA; Gauldie J; Schultz-Cherry S
    PLoS Pathog; 2010 Oct; 6(10):e1001136. PubMed ID: 20949074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza virus neuraminidase activates latent transforming growth factor beta.
    Schultz-Cherry S; Hinshaw VS
    J Virol; 1996 Dec; 70(12):8624-9. PubMed ID: 8970987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
    Changsom D; Lerdsamran H; Wiriyarat W; Chakritbudsabong W; Siridechadilok B; Prasertsopon J; Noisumdaeng P; Masamae W; Puthavathana P
    PLoS One; 2016; 11(4):e0153183. PubMed ID: 27054879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
    Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
    Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza viral neuraminidase primes bacterial coinfection through TGF-β-mediated expression of host cell receptors.
    Li N; Ren A; Wang X; Fan X; Zhao Y; Gao GF; Cleary P; Wang B
    Proc Natl Acad Sci U S A; 2015 Jan; 112(1):238-43. PubMed ID: 25535343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
    Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
    Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.
    Yen HL; Ilyushina NA; Salomon R; Hoffmann E; Webster RG; Govorkova EA
    J Virol; 2007 Nov; 81(22):12418-26. PubMed ID: 17855542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.
    Tian X; Landreth S; Lu Y; Pandey K; Zhou Y
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The special neuraminidase stalk-motif responsible for increased virulence and pathogenesis of H5N1 influenza A virus.
    Zhou H; Yu Z; Hu Y; Tu J; Zou W; Peng Y; Zhu J; Li Y; Zhang A; Yu Z; Ye Z; Chen H; Jin M
    PLoS One; 2009 Jul; 4(7):e6277. PubMed ID: 19609439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Immune Adaptor ADAP Regulates Reciprocal TGF-β1-Integrin Crosstalk to Protect from Influenza Virus Infection.
    Li C; Jiao S; Wang G; Gao Y; Liu C; He X; Zhang C; Xiao J; Li W; Zhang G; Wei B; Chen H; Wang H
    PLoS Pathog; 2015 Apr; 11(4):e1004824. PubMed ID: 25909459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
    Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice.
    Hooper KA; Crowe JE; Bloom JD
    J Virol; 2015 Apr; 89(7):3737-45. PubMed ID: 25609803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly pathogenic avian influenza H5N1 virus delays apoptotic responses via activation of STAT3.
    Hui KP; Li HS; Cheung MC; Chan RW; Yuen KM; Mok CK; Nicholls JM; Peiris JS; Chan MC
    Sci Rep; 2016 Jun; 6():28593. PubMed ID: 27344974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
    Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
    PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo.
    Haasbach E; Droebner K; Vogel AB; Planz O
    J Interferon Cytokine Res; 2011 Jun; 31(6):515-25. PubMed ID: 21323570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
    Ilyushina NA; Govorkova EA; Gray TE; Bovin NV; Webster RG
    PLoS Pathog; 2008 Apr; 4(4):e1000043. PubMed ID: 18404209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.